Background: The study is based on the fact that a lower volume of local anesthetic drugs for ultrasound-guided supraclavicular brachial plexus block is useful for upper limb surgeries lasting for a shorter duration, and result in a lower incidence of complications. Aim: The aim of this study is to compare the effectiveness of 35 mL of 0.5% ropivacaine with 20 mL of 0.5% ropivacaine in ultrasound-guided supraclavicular brachial plexus block for upper limb surgery. Setting: Patients undergoing upper limb surgery in an industry-based government hospital in New Delhi, India. Patients were followed in the operation theater and the recovery room. Design: The study design involves a prospective, double-blind, randomized controlled trial. Materials and Methods: A total of 40 participants were recruited for this study. Twenty participants in each group (referred to as group 20 and 30) received 20 mL and 35 mL of 0.5% ropivacaine, respectively, in ultrasound-guided supraclavicular brachial plexus block. Statistical Analysis: The statistical analysis was performed using the software SPSS version 15 and a value of P < 0.05% was considered statistically significant. The statistical tests used included Student's t -test to compare values between the two groups for the mean of parametric data, Mann–Whitney U-test for a median of nonparametric data, and Chi-square test or Fisher's exact test for the categorical data. Results: The sensory and motor block onset in group 20 was 18.06 ± 3.04 and 23.89 ± 2.14 min, respectively. The sensory and motor block onset in group 30 was 17 ± 2.01 and 23.75 ± 2.22 min, respectively. The duration of analgesia in group 20 and 30 was 575.56 ± 104.39 and 730.75 ± 102.09 min, respectively ( P < 0.001). Conclusion: The onset of sensory and motor block of 20 mL of 0.5% ropivacaine is comparable to 35 mL of 0.5% ropivacaine for supraclavicular brachial plexus block for upper limb surgery. There was a 21% decrease in the duration of analgesia with a decrease in volume of 0.5% ropivacaine from 35 mL to 20 mL.
Background: Pain is the most common complain causing distress to the patients in immediate postoperative period. Various studies have shown that transverse abdominal plane (TAP) 13 block is effective modality for postoperative pain relief using ropivacaine or bupivacaine. But duration of these blocks with local anesthetics only is limited to few hours. The present study was conducted with the aim to compare the postoperative analgesia amongst subjects receiving ropivacaine and clonidine versus ropivacaine alone. Subjects and Methods: The present prospective and double blinded study involving 70 patients was performed for a period of 2 years at the Department of Anesthesiology. Monitors were attached and baseline (preoperative) heart rate by ECG, systolic and diastolic blood pressure was measured by noninvasive blood pressure monitoring. The duration of postoperative analgesia and complications like nausea, vomiting or any other were noted during the procedure. Student t test was used for statistical analysis and probability value of less than 0.05 was considered as significant. Results: Abdominal Hysterectomy was performed in 4 patients in Group c and 6 patients in Group R. Hernioplasty was performed in 5 patients in Group c and 7 patients in Group R. The mean time for first dose in Group c was 646.83 mins and in group R was 393.43 mins. The mean time for second dose in Group c was 1284.89 mins and in group R was 393.43 mins. Conclusion: TAP block under USG guidance should be used to provide better analgesia in postoperative Period. Adjuvants like clonidine should be used along with local anesthetics for prolongation of analgesic effect of TAP block in post-operative period.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.